Wave of Warning Letters to Foreign OTC Drug Manufacturing Facilities Following Remote Records Requests
FDA Law Blog
AUGUST 10, 2023
Cato — On August 3rd, FDA issued 11 warning letters to foreign facilities registered as OTC drug manufacturers. Section 704(a)(4) was added to the FDCA by the Food and Drug Administration Safety and Innovation Action (FDASIA) in July 2012. By McKenzie E.
Let's personalize your content